- 期刊
晚期口腔癌以口服Uracil-Tegafur施行術後輔助性化學治療
Oral Uracil and Tegafur as a Post-operative Adjuvant Chemotherapy in High-risk Oral Squamous Cell Carcinoma Patients
摘要
目的：研究晚期口腔癌病患腫瘤廣泛性切除及淋巴廓清術手術後，接受口服UFUR作為術後輔助性化療是否有效及評估整體的存活率。方法：本次研究從2003年1月至2007年12月針對在馬偕紀念醫院口腔顎面外科，切片檢查證實為口腔鱗狀細胞癌的病例，在本科接受腫瘤廣泛性切除及頸部淋巴廓清術手術之原發性病理分期第三及第四期口腔鱗狀細胞癌共80個病例，隨機分為二組。第一組為接受口服UFUR的輔助化療，劑量為一天兩次且每150 mg的Tegafur配合224 mg的Uracil持續一年，另一組則不接受口服UFUR的輔助化療。結果：接受UFUR治療者四年整體平均存活率為83.6％，沒有接受UFUR治療者存活率為76.9％，顯示二組的平均存活率具有統計學上的意義（P＝0.03），而副作用方面在使用口服UFUR患者有發生嗜中性白血球減少症2.5％、貧血症2.5％、噁心嘔吐7.5％、皮膚疹20％，但接受口服UFUR治療者與沒有接受治療者副作用發生的比率並無統計學上之差異，在二組且發生的比率並無統計學上之差異。結論：低劑量口服UFUR作為輔助化療，對於接受口腔癌手術切除的晚期的病患是有幫助的，除了有較低的毒性反應外，可以使口腔癌病人存活率升高，因此整體上對口腔癌晚期病人是有益的。所以我們認為口服UFUR療程可以提供給口腔癌晚期術後高度危險群的病患，做為一個輔助的治療方法。
並列摘要
Aim: This retrospective study was to evaluate the effectiveness of oral Uracil-Tegafur (UFUR) given as postoperative adjuvant treatment to patients with high-risk oral squamous cell carcinoma(OSCC).Material and Methods: OSCC patients with T4 and cervical node-negative; T2 or T3 with N1 received oral UFUR as postoperative adjuvant chemotherapy. In the same time period who with the similar stages without taking oral UFUR after the surgery were enrolled for the analysis. All the patients did not receive the post-operative radiotherapy or other systemic chemotherapy. Overall survival (OS) and toxicity were evaluated in these two groups. The hypothesis was that oral UFUR was an effective adjuvant treatment in advanced resected OSCC.Results: Between January 2003 and December 2007, a total of 80 patients were enrolled in this review. The median follow-up time was 4 years. The OS rates at 4 years were 83.6% in the oral UFUR arm and 76.9% without UFT therapy. (P=0.03) The toxicity profiles did not differ between the two groups.Conclusion: Patient with high-risk OSCC received oral UFUR had better prognosis than those who without taking oral UFUR. Oral UFUR is a promising postoperative adjuvant chemotherapy in high-risk OSCC.